Advertisement

Cost-Effectiveness of a Specialized Breathlessness Service Versus Usual Care for Patients With Advanced Diseases

Published:September 28, 2022DOI:https://doi.org/10.1016/j.jval.2022.08.002

      Abstract

      Objectives

      The Munich Breathlessness Service (MBS) significantly improved control of breathlessness measured by the Chronic Respiratory Questionnaire (CRQ) Mastery in a randomized controlled fast track trial with waitlist group design spanning 8 weeks in Germany. This study aimed to assess the within-trial cost-effectiveness of MBS from a societal perspective.

      Methods

      Data included generic (5-level version of EQ-5D) health-related quality of life and disease-specific CRQ Mastery. Quality-adjusted life years (QALYs) were calculated based on 5-level version of EQ-5D utilities valued with German time trade-off. Direct medical costs and productivity loss were calculated based on standardized unit costs. Incremental cost-effectiveness ratios (ICER) and cost-effectiveness–acceptance curves were calculated using adjusted mean differences (AMD) in costs (gamma-distributed model) and both effect parameters (Gaussian-distributed model) and performing 1000 simultaneous bootstrap replications. Potential gender differences were investigated in stratified analyses.

      Results

      Between March 2014 and April 2019, 183 eligible patients were enrolled. MBS intervention demonstrated significantly better effects regarding generic (AMD of QALY gains of 0.004, 95% confidence interval [CI] 0.0003 to 0.008) and disease-specific health-related quality of life at nonsignificantly higher costs (AMD of €605 [95% CI −1109 to 2550]). At the end of the intervention, the ICER was €152 433/QALY (95% CI −453 545 to 1 625 903) and €1548/CRQ Mastery point (95% CI −3093 to 10 168). Intervention costs were on average €357 (SD = 132). Gender-specific analyses displayed dominance for MBS in males and higher effects coupled with significantly higher costs in females.

      Conclusions

      Our results show a high ICER for MBS. Considering dominance for MBS in males, implementing MBS on approval within the German health care system should be considered.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Value in Health
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Garcia-Polo C.
        • Alcazar-Navarrete B.
        • Ruiz-Iturriaga L.A.
        • et al.
        Factors associated with high healthcare resource utilisation among COPD patients.
        Respir Med. 2012; 106: 1734-1742
        • Vermylen J.H.
        • Szmuilowicz E.
        • Kalhan R.
        Palliative care in COPD: an unmet area for quality improvement.
        Int J Chron Obstruct Pulmon Dis. 2015; 10: 1543-1551
        • Barbera L.
        • Taylor C.
        • Dudgeon D.
        Why do patients with cancer visit the emergency department near the end of life?.
        CMAJ. 2010; 182: 563-568
        • Kupper N.
        • Bonhof C.
        • Westerhuis B.
        • Widdershoven J.
        • Denollet J.
        Determinants of dyspnea in chronic heart failure.
        J Card Fail. 2016; 22: 201-209
        • Mathers C.D.
        • Loncar D.
        Projections of global mortality and burden of disease from 2002 to 2030.
        PLOS Med. 2006; 3: e442
        • Huang C.
        • Huang L.
        • Wang Y.
        • et al.
        6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.
        Lancet. 2021; 397: 220-232
        • Mandal S.
        • Barnett J.
        • Brill S.E.
        • et al.
        ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalization for COVID-19.
        Thorax. 2020; 76 (thoraxjnl-2020-215818)
        • Currow D.C.
        • Dal Grande E.
        • Ferreira D.
        • Johnson M.J.
        • McCaffrey N.
        • Ekstrom M.
        Chronic breathlessness associated with poorer physical and mental health-related quality of life (SF-12) across all adult age groups.
        Thorax. 2017; 72: 1151-1153
        • Ekstrom M.
        • Williams M.
        • Johnson M.J.
        • Huang C.
        • Currow D.C.
        Agreement between breathlessness severity and unpleasantness in people with chronic breathlessness: a longitudinal clinical study.
        J Pain Symptom Manag. 2019; 57: 715-723 e5
        • Detournay B.
        • Pribil C.
        • Fournier M.
        • et al.
        The SCOPE study: health-care consumption related to patients with chronic obstructive pulmonary disease in France.
        Value Health. 2004; 7: 168-174
        • Dzingina M.D.
        • Reilly C.C.
        • Bausewein C.
        • et al.
        Variations in the cost of formal and informal health care for patients with advanced chronic disease and refractory breathlessness: A cross-sectional secondary analysis.
        Palliat Med. 2017; 31: 369-377
        • Hutchinson A.
        • Pickering A.
        • Williams P.
        • Bland J.M.
        • Johnson M.J.
        Breathlessness and presentation to the emergency department: a survey and clinical record review.
        BMC Pulm Med. 2017; 17: 53
        • Laribi S.
        • Keijzers G.
        • van Meer O.
        • et al.
        Epidemiology of patients presenting with dyspnea to emergency departments in Europe and the Asia-Pacific region.
        Eur J Emerg Med. 2019; 26: 345-349
        • Booth S.
        • Moffat C.
        • Farquhar M.
        • Higginson I.J.
        • Burkin J.
        Developing a breathlessness intervention service for patients with palliative and supportive care needs, irrespective of diagnosis.
        J Palliat Care. 2011; 27: 28-36
        • Bausewein C.
        • Jolley C.
        • Reilly C.
        • et al.
        Development, effectiveness and cost-effectiveness of a new out-patient Breathlessness Support Service: study protocol of a phase III fast-track randomised controlled trial.
        BMC Pulm Med. 2012; 12: 58
        • Farquhar M.C.
        • Prevost A.T.
        • McCrone P.
        • et al.
        Is a specialist breathlessness service more effective and cost-effective for patients with advanced cancer and their carers than standard care? Findings of a mixed-method randomised controlled trial.
        BMC Med. 2014; 12: 194
        • Farquhar M.C.
        • Prevost A.T.
        • McCrone P.
        • et al.
        The clinical and cost effectiveness of a breathlessness intervention service for patients with advanced non-malignant disease and their informal carers: mixed findings of a mixed method randomised controlled trial.
        Trials. 2016; 17: 185
        • Higginson I.J.
        • Bausewein C.
        • Reilly C.C.
        • et al.
        An integrated palliative and respiratory care service for patients with advanced disease and refractory breathlessness: a randomised controlled trial.
        Lancet Respir Med. 2014; 2: 979-987
        • Philip J.
        • Collins A.
        • Smallwood N.
        • et al.
        Referral criteria to palliative care for patients with respiratory disease: a systematic review.
        Eur Respir J. 2021; 582004307
        • Fadol A.P.
        • Patel A.
        • Shelton V.
        • Krause K.J.
        • Bruera E.
        • Palaskas N.L.
        Palliative care referral criteria and outcomes in cancer and heart failure: a systematic review of literature.
        Cardiooncology. 2021; 7: 32
        • Schunk M.
        • Le L.
        • Syunyaeva Z.
        • et al.
        Effectiveness of a specialised breathlessness service for patients with advanced disease in Germany: a pragmatic fast track randomised controlled trial (BreathEase).
        Eur Respir J. 2021; 582002139
        • Brighton L.J.
        • Miller S.
        • Farquhar M.
        • et al.
        Holistic services for people with advanced disease and chronic breathlessness: a systematic review and meta-analysis.
        Thorax. 2019; 74: 270-281
        • Buttery S.C.
        • Zysman M.
        • Vikjord S.A.A.
        • Hopkinson N.S.
        • Jenkins C.
        • Vanfleteren L.
        Contemporary perspectives in COPD: patient burden, the role of gender and trajectories of multimorbidity.
        Respirology. 2021; 26: 419-441
        • Nguyen L.P.
        • Beck E.
        • Cayetano K.
        • Li C.S.
        • Hardin K.
        Differential pulmonary rehabilitation outcomes in patients with and without COPD: ROLE OF GENDER.
        J Cardiopulm Rehabil Prev. 2017; 37: 350-355
        • Truby L.K.
        • O’Connor C.
        • Fiuzat M.
        • et al.
        Sex differences in quality of life and clinical outcomes in patients with advanced heart failure: insights from the PAL-HF trial.
        Circ Heart Fail. 2020; 13e006134
        • Nipp R.D.
        • Greer J.A.
        • El-Jawahri A.
        • et al.
        Age and gender moderate the impact of early palliative care in metastatic non-small cell lung cancer.
        Oncologist. 2016; 21: 119-126
        • Schunk M.
        • Berger U.
        • Le L.
        • et al.
        BreathEase: rationale, design and recruitment of a randomised trial and embedded mixed-methods study of a multiprofessional breathlessness service in early palliative care.
        ERJ Open Res. 2021; 7: 00228-2020
        • Seidl H.
        • Bowles D.
        • Bock J.O.
        • et al.
        FIMA–questionnaire for health-related resource use in an elderly population: development and pilot study [FIMA—Fragebogen zur Erhebung von Gesundheitsleistungen im Alter: Entwicklung und Pilotstudie].
        Gesundheitswesen. 2015; 77: 46-52
        • Seidl H.
        • Hein L.
        • Scholz S.
        • et al.
        Validation of the FIMA questionnaire for health-related resource use against medical claims data: the role played by length of recall period [Validierung des FIMA-Fragebogens zur Inanspruchnahme von Versorgungsleistungen anhand von Routinedaten der Krankenversicherung: welchen Einfluss hat der Erinnerungszeitraum?].
        Gesundheitswesen. 2021; 83: 66-74
        • Bock J.O.
        • Brettschneider C.
        • Seidl H.
        • et al.
        Calculation of standardised unit costs from a societal perspective for health economic evaluation [Ermittlung standardisierter Bewertungssatze aus gesellschaftlicher Perspektive fur die gesundheitsokonomische Evaluation].
        Gesundheitswesen. 2015; 77: 53-61
      1. Vertrag gemäß § 89 SGB XI vom 28.05.2014. AOK.
      2. Bundesministerium für Gesundheit. Pflegeleistungen 2015. BMG.
      3. Gutachten zur ambulanten Notfallversorgung im Krankenhaus. DGINA.
      4. Fallpauschalenkatalog, G-DRG-version 2016, anlage;5(S):138. Fallpauschalenkatalog.
        • Kalbe P.
        Abrechnung ambulanter und belegärztlicher Operationen. BDC.
      5. Vertrag nach § Vol. 127:Abs 2 SGB V. SGB.
      6. Sittig B. Was SAPV wirklich kostet. Angew Schmerzther Palliativmedizin. 2009;Sonderheft(1):1-5.

      7. Arzneimittelstammdatei WIDO.
      8. Bundesanstalt für Arbeitsschutz Volkswirtschaftliche Kosten durch Arbeitsunfähigkeit. BAUA.
        • Herdman M.
        • Gudex C.
        • Lloyd A.
        • et al.
        Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).
        Qual Life Res. 2011; 20: 1727-1736
        • Janssen M.F.
        • Pickard A.S.
        • Golicki D.
        • et al.
        Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study.
        Qual Life Res. 2013; 22: 1717-1727
        • Ludwig K.
        • Graf von der Schulenburg J.M.
        • Greiner W.
        German value set for the EQ-5D-5L.
        Pharmacoeconomics. 2018; 36: 663-674
        • Bae E.
        • Choi S.E.
        • Lee H.
        • Shin G.
        • Kang D.
        Validity of EQ-5D utility index and minimal clinically important difference estimation among patients with chronic obstructive pulmonary disease.
        BMC Pulm Med. 2020; 20: 73
        • Manca A.
        • Hawkins N.
        • Sculpher M.J.
        Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility.
        Health Econ. 2005; 14: 487-496
        • Schunemann H.J.
        • Puhan M.
        • Goldstein R.
        • Jaeschke R.
        • Guyatt G.H.
        Measurement properties and interpretability of the Chronic respiratory disease questionnaire (CRQ).
        COPD. 2005; 2: 81-89
        • Williams J.E.
        • Singh S.J.
        • Sewell L.
        • Guyatt G.H.
        • Morgan M.D.
        Development of a self-reported Chronic Respiratory Questionnaire (CRQ-SR).
        Thorax. 2001; 56: 954-959
        • Jaeschke R.
        • Singer J.
        • Guyatt G.H.
        Measurement of health status. Ascertaining the minimal clinically important difference.
        Control Clin Trials. 1989; 10: 407-415
        • Faria R.
        • Gomes M.
        • Epstein D.
        • White I.R.
        A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials.
        Pharmacoeconomics. 2014; 32: 1157-1170
        • Abernethy A.P.
        • Shelby-James T.
        • Fazekas B.S.
        • Woods D.
        • Currow D.C.
        The Australia-modified Karnofsky Performance Status (AKPS) scale: a revised scale for contemporary palliative care clinical practice [ISRCTN81117481].
        BMC Palliat Care. 2005; 4: 7
        • Charlson M.E.
        • Pompei P.
        • Ales K.L.
        • MacKenzie C.R.
        A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
        J Chronic Dis. 1987; 40: 373-383
        • Manning W.G.
        • Basu A.
        • Mullahy J.
        Generalized modeling approaches to risk adjustment of skewed outcomes data.
        J Health Econ. 2005; 24: 465-488
        • Mutubuki E.N.
        • El Alili M.
        • Bosmans J.E.
        • et al.
        The statistical approach in trial-based economic evaluations matters: get your statistics together.
        BMC Health Serv Res. 2021; 21: 475
        • Graubard B.I.
        • Korn E.L.
        Predictive margins with survey data.
        Biometrics. 1999; 55: 652-659
        • Drummond M.
        • Sculpher M.
        • Claxton K.
        • Stoddart G.
        • Torrance G.
        Methods for the Economic Evaluation of Health Care Programmes.
        Oxford university press, Oxford, United Kingdom2015
        • Husereau D.
        • Drummond M.
        • Petrou S.
        • et al.
        Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.
        Value Health. 2013; 16: e1-e5
        • Mittmann N.
        • Liu N.
        • Porter J.M.
        • et al.
        End-of-life home care utilization and costs in patients with advanced colorectal cancer.
        J Community Support Oncol. 2014; 12: 92-98
        • Tamir O.
        • Singer Y.
        • Shvartzman P.
        Taking care of terminally-ill patients at home - the economic perspective revisited.
        Palliat Med. 2007; 21: 537-541
        • Johnson M.J.
        • Kanaan M.
        • Richardson G.
        • et al.
        A randomised controlled trial of three or one breathing technique training sessions for breathlessness in people with malignant lung disease.
        BMC Med. 2015; 13: 213
        • Wichmann A.B.
        • Adang E.M.
        • Stalmeier P.F.
        • et al.
        The use of quality-adjusted life years in cost-effectiveness analyses in palliative care: mapping the debate through an integrative review.
        Palliat Med. 2017; 31: 306-322
        • Puhan M.A.
        • Guyatt G.H.
        • Goldstein R.
        • et al.
        Relative responsiveness of the Chronic Respiratory Questionnaire, St. Georges Respiratory Questionnaire and four other health-related quality of life instruments for patients with chronic lung disease.
        Respir Med. 2007; 101: 308-316
        • Yang Y.T.
        • Mahon M.M.
        Palliative care for the terminally ill in America: the consideration of QALYs, costs, and ethical issues.
        Med Health Care Philos. 2012; 15: 411-416
        • Reckers-Droog V.
        • van Exel J.
        • Brouwer W.
        Willingness to pay for quality and length of life gains in end of life patients of different ages.
        Soc Sci Med. 2021; 279113987
        • Schiebinger L.
        • Leopold S.S.
        • Miller V.M.
        Editorial policies for sex and gender analysis.
        Lancet. 2016; 388: 2841-2842
        • Wagner A.D.
        • Oertelt-Prigione S.
        • Adjei A.
        • et al.
        Gender medicine and oncology: report and consensus of an ESMO workshop.
        Ann Oncol. 2019; 30: 1914-1924
        • Boni-Saenz A.A.
        • Dranove D.
        • Emanuel L.L.
        • Lo Sasso A.T.
        The price of palliative care: toward a complete accounting of costs and benefits.
        Clin Geriatr Med. 2005; 21: 147-163, ix